In vitro models for neuropathic pain phenotypic screening in brain therapeutics
Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved..
The discovery of brain therapeutics faces a significant challenge due to the low translatability of preclinical results into clinical success. To address this gap, several efforts have been made to obtain more translatable neuronal models for phenotypic screening. These models allow the selection of active compounds without predetermined knowledge of drug targets. In this review, we present an overview of various existing models within the field, examining their strengths and limitations, particularly in the context of neuropathic pain research. We illustrate the usefulness of these models through a comparative review in three crucial areas: i) the development of novel phenotypic screening strategies specifically for neuropathic pain, ii) the validation of the models for both primary and secondary screening assays, and iii) the use of the models in target deconvolution processes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:202 |
|---|---|
| Enthalten in: |
Pharmacological research - 202(2024) vom: 26. März, Seite 107111 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Martínez, A L [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 27.03.2024 Date Revised 27.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.phrs.2024.107111 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368726622 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368726622 | ||
| 003 | DE-627 | ||
| 005 | 20240327235854.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240222s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.phrs.2024.107111 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1351.xml |
| 035 | |a (DE-627)NLM368726622 | ||
| 035 | |a (NLM)38382648 | ||
| 035 | |a (PII)S1043-6618(24)00055-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Martínez, A L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a In vitro models for neuropathic pain phenotypic screening in brain therapeutics |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.03.2024 | ||
| 500 | |a Date Revised 27.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a The discovery of brain therapeutics faces a significant challenge due to the low translatability of preclinical results into clinical success. To address this gap, several efforts have been made to obtain more translatable neuronal models for phenotypic screening. These models allow the selection of active compounds without predetermined knowledge of drug targets. In this review, we present an overview of various existing models within the field, examining their strengths and limitations, particularly in the context of neuropathic pain research. We illustrate the usefulness of these models through a comparative review in three crucial areas: i) the development of novel phenotypic screening strategies specifically for neuropathic pain, ii) the validation of the models for both primary and secondary screening assays, and iii) the use of the models in target deconvolution processes | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Early drug discovery | |
| 650 | 4 | |a Felodipine (PubChem CID: 3333) | |
| 650 | 4 | |a Immortalized cell lines | |
| 650 | 4 | |a In vitro models | |
| 650 | 4 | |a In vitro pharmacology | |
| 650 | 4 | |a Melatonin (PubChem CID: 896) | |
| 650 | 4 | |a Neuropathic pain | |
| 650 | 4 | |a Nicardipine (PubChem CID: 4474) | |
| 650 | 4 | |a Nimodipine (PubChem CID: 4497) | |
| 650 | 4 | |a Nitrendipine (PubChem CID: 4507) | |
| 650 | 4 | |a Phenotypic screening | |
| 650 | 4 | |a Pregabalin (PubChem CID: 5486971) | |
| 650 | 4 | |a Protriptyline (PubChem CID: 4976) | |
| 650 | 4 | |a Rilpivirine (PubChem CID: 6451164) | |
| 650 | 4 | |a Vincristine (PubChem CID: 5978) | |
| 650 | 4 | |a Zalcitabine (PubChem CID: 24066) | |
| 650 | 4 | |a α-lipoic acid (PubChem CID: 53259805) | |
| 700 | 1 | |a Brea, J |e verfasserin |4 aut | |
| 700 | 1 | |a López, D |e verfasserin |4 aut | |
| 700 | 1 | |a Cosme, N |e verfasserin |4 aut | |
| 700 | 1 | |a Barro, M |e verfasserin |4 aut | |
| 700 | 1 | |a Monroy, X |e verfasserin |4 aut | |
| 700 | 1 | |a Burgueño, J |e verfasserin |4 aut | |
| 700 | 1 | |a Merlos, M |e verfasserin |4 aut | |
| 700 | 1 | |a Loza, M I |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacological research |d 1992 |g 202(2024) vom: 26. März, Seite 107111 |w (DE-627)NLM012597384 |x 1096-1186 |7 nnns |
| 773 | 1 | 8 | |g volume:202 |g year:2024 |g day:26 |g month:03 |g pages:107111 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.phrs.2024.107111 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 202 |j 2024 |b 26 |c 03 |h 107111 | ||